

# Characterising negative symptoms in schizophrenia: CHANSS study protocol

Noham Wolpe, Clàudia Aymerich, Ying Jin, Marta Martin-Subero, Paloma Fuentes-Perez, Claudia Ovejas-Catalan, Sara Salas-Rad, Renata Zirilli, Sophie Shatford, Rebecca Cox, Megan Cartier, Ana Catalan, Anna Mane, John Pratt, Lisa Airey, Paul Stanley, Adrienne Close, Andrew Hall, Javier Vazquez-Bourgon, Francesco del Santo, Maria-Paz Garcia-Portilla, Nuria Segarra, Yi-Jie Zhao, Paul C. Fletcher, Masud Husain, Peter B. Jones and Emilio Fernandez-Egea

## Background

Negative symptoms in schizophrenia, particularly motivational deficits, pose significant challenges to treatment and recovery. Despite their profound impact on functional outcomes, these symptoms remain poorly understood and inadequately addressed by current interventions.

## Aims

The CHANSS (Characterising Negative Symptoms in Schizophrenia) study aims to dissect the cognitive mechanisms underlying motivational impairments by focusing on three interconnected domains: executive cognition, motivational cognition and meta-cognition.

## Method

This large, international, cross-sectional study recruits a heterogeneous sample of patients across illness stages – from first-episode psychosis to treatment-resistant schizophrenia – and uses a comprehensive cognitive battery, clinical scales, self-report measures and computerised cognitive tasks. Four novel tasks assess key processes in motivated behaviour: option generation, reward-based decision-making, risk sensitivity and performance self-evaluation. By incorporating control for secondary influences like depression, psychosis, sedation and illness chronicity, the study seeks to identify distinct cognitive and behavioural subtypes within motivational dysfunction.

## Results

CHANSS tests the hypothesis that specific patient profiles exhibit predominant impairments in one or more cognitive domains, which may differentially affect goal-directed behaviour. The study's design allows exploration of hierarchical relationships between cognitive processes, such as how neurocognitive deficits may cascade to impair motivation and self-evaluation.

## Conclusions

Ultimately, CHANSS aims to advance mechanistic understanding of motivational deficits in schizophrenia and pave the way for personalised, targeted interventions. Its findings may inform future clinical trials and contribute to a shift away from one-size-fits-all approaches towards more effective, stratified treatment strategies in schizophrenia.

## Keywords

Apathy; motivation; negative symptoms; cognition; computational modelling.

## Copyright and usage

© The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.


Schizophrenia is a chronic and disabling psychiatric disorder affecting approximately 1% of the global population and remains a leading cause of disability worldwide.<sup>1</sup> Although considerable research efforts have focused on the pathophysiology and treatment of psychosis, negative symptoms have historically received less attention despite their significant impact on patients' long-term outcomes.<sup>2</sup> Indeed, negative symptoms frequently prove resistant to both pharmacological and psychosocial interventions, substantially impairing patients' social and occupational functioning.<sup>3</sup>

Negative symptoms have been conceptualised along two principal dimensions: diminished emotional expression (blunted affect and alogia) and deficits in motivation and pleasure (avolition, anhedonia and asociality).<sup>4</sup> Emerging evidence suggests these dimensions are psychometrically and potentially biologically distinct and remain independent clinical entities over time.<sup>5–7</sup> Controversially, much of the research into negative symptoms has approached them as a unitary construct, possibly impeding the development of effective therapeutic strategies. A multifaceted approach, in which each dimension is studied independently, may enhance our understanding of the distinct underlying mechanisms – defined here as the specific cognitive mechanisms that may causally contribute to core deficits in schizophrenia. Given its critical role in determining functional outcomes, our primary focus is on the mechanisms underlying motivational impairment.

Motivational deficits in schizophrenia can be conceptualised as a syndrome involving multiple mechanisms but distinguishing causal factors from confounders has been challenging. For consistency with terminology used in other clinical fields and in neuroscience, we use the term 'apathy' to refer to the common observable endpoint of these mechanisms: a reduction in goal-directed behaviour.<sup>8</sup> Deconstructing apathy in schizophrenia into its specific cognitive mechanisms can help to delineate precise deficits, potentially deepening our understanding of schizophrenia's complex symptoms and guiding targeted interventions.<sup>9</sup>

We identify three key candidate mechanisms underlying apathy in schizophrenia: executive dysfunction, specific motivational processing of cost and benefit, and maladaptive beliefs,<sup>9</sup> which, for simplicity, we term executive cognition, motivational cognition and meta-cognition. First, executive cognition refers to the capacity to plan, initiate and sustain goal-directed actions,<sup>10</sup> which is strongly associated with apathy in schizophrenia.<sup>11</sup> Executive cognition itself relies on foundational cognitive 'building blocks' such as attention and working memory, which are commonly assessed using standard neurocognitive assessment batteries, such as the Brief Assessment of Cognition<sup>12</sup> and MATRICS, and which are commonly impaired in schizophrenia. Second, motivational cognition refers to the specific cognitive mechanisms related to the decision of whether to engage in goal-directed actions and, if so,

Characterising Negative Symptoms in Schizophrenia (CHANSS)



**Fig. 1** Schematic of the theoretical and experimental framework. The project Characterising Negative Symptoms in Schizophrenia (CHANSS) aims to assess each of the three key cognitive mechanisms hypothesised to underlie apathy in schizophrenia. It will quantify their relative contribution to apathy and their differential associations with clinical variables relevant to apathy, such as illness stage and depression.

which action to choose. The decision requires the valuation of effort and reward,<sup>13</sup> and has been shown to be altered in schizophrenia.<sup>14</sup> Motivational cognition has been assessed using decision-making paradigms.<sup>15</sup> Third, meta-cognition encompasses the ability to monitor and evaluate one’s own performance; in schizophrenia, this is often characterised by defeatist beliefs and low self-efficacy, which can further inhibit motivation.<sup>16</sup>

These three cognitive mechanisms are likely to be interrelated and partially dependent on one another, which would make it conceptually and analytically difficult to separate their independent contribution to apathy in schizophrenia. However, the relative contributions of executive, motivational and meta-cognition mechanisms to apathy would vary significantly between individuals with schizophrenia. Clarifying these contributions is essential for developing targeted interventions and refining existing therapeutic approaches. Moreover, clarifying the clinical factors associated with specific cognitive mechanisms is essential for adapting treatment. For example, secondary causes of negative symptoms, such as sedation related to antipsychotic medication,<sup>6</sup> depression, disorganisation, psychosis and social stigma, can all contribute differentially to these cognitive mechanisms. Similarly, illness stage has been shown to differentially influence motivational cognition: two studies employing the same effort-based decision-making task in patients with schizophrenia found distinct results in patient populations at different illness stages. Specifically, individuals with chronic schizophrenia are less inclined to accept offers involving high rewards regardless of effort.<sup>15</sup> By contrast, individuals in earlier stages of the illness were less inclined to accept offers demanding high effort regardless of reward,<sup>17</sup> indicating potentially different meta-cognition contributions. Together, it is important to measure the three cognitive mechanisms, alongside key clinical variables relevant for apathy.

The CHANSS (Characterising Negative Symptoms in Schizophrenia) project aims to investigate the cognitive mechanisms underlying apathy in schizophrenia, while measuring common secondary factors affecting apathy. To this end, the project will utilise a large, multi-site, multicultural and heterogeneous sample of individuals diagnosed with schizophrenia at various illness stages, from first-episode psychosis to treatment-resistant schizophrenia (TRS). This diversity enhances the generalisability of findings and allows exploration of how the cognitive mechanisms relevant to apathy vary across the illness spectrum.<sup>18</sup> The principal aim of the project is to identify different subtypes of

motivational impairments in patients based on the relative contribution of the three cognitive mechanisms underlying apathy. The study employs an extensive battery of psychometric and cognitive assessments, alongside computer-based tasks designed to measure executive, motivational and meta-cognition aspects of goal-directed behaviour (Fig. 1).

General hypotheses:

- (a) Group differences will emerge across all tasks, with patients performing less optimally than controls on tasks related to the three cognitive mechanisms.
- (b) Some of these differences might be due to potentially treatable secondary causes of poor motivation (e.g. depression or drug-induced sedation). These secondary factors will selectively impair specific mechanisms within the motivational syndrome.
- (c) Patients can be grouped into clusters or subtypes according to behavioural differences and the relative contribution of the three (executive, motivational and meta-) cognition components.
- (d) A hierarchical effect will be observed, whereby dysfunction in more basic cognitive mechanisms (e.g. executive dysfunction) would disrupt higher-level mechanisms (e.g. motivational and meta-cognition).

## Method

### Study design

The CHANSS study is a multicentre, experimental, cross-sectional study designed to investigate the cognitive underpinnings of motivation in schizophrenia. The study employs a comprehensive battery of clinical assessments, cognitive tasks and self-reported measures to evaluate motivational deficits across different illness stages, including first-episode psychosis and TRS.

Recruitment dates: recruitment started in May 2021 and is expected to continue until July 2025.

### Study sites

The CHANSS study was conducted across multiple international research centres, including academic institutions and mental health

centres in the UK (Cambridge, London, Humber and Doncaster), Spain (Barcelona, Bilbao, Oviedo and Santander) and China (Shanghai). In the UK, the study benefits from the support of the National Institute for Health and Care Research Clinical Research Network (NIHR-CRN), which facilitates participant recruitment, site coordination and data management.

### Inclusion and exclusion criteria

Inclusion criteria:

- (a) age between 18 and 65 years;
- (b) diagnosis of schizophrenia according to the International Classification of Diseases, 10th Revision (ICD-10)<sup>19</sup> criteria, with more than one year of diagnosis;
- (c) stable antipsychotic medication regimen for at least six weeks prior to study enrolment;
- (d) capacity to provide informed consent.

Exclusion criteria:

- (a) presence of neurological disorders or significant medical conditions that may affect cognitive functioning;
- (b) history of traumatic brain injury with loss of consciousness exceeding 5 min;
- (c) current substance use disorder (excluding nicotine) within the past six months;
- (d) established diagnosis of neurodevelopmental disorder;
- (e) intellectual disability (IQ < 70);
- (f) use of anticholinergic medication, except for hyoscine in cases of clozapine-induced sialorrhea.

### Ethical considerations

The study protocol has been reviewed and approved by the relevant institutional review boards and ethics committees at each participating site. In the UK, the protocol received ethical approval from the Health Research Authority (HRA; IRAS:295622; 21/WA/0056) and was registered with the NIHR Clinical Research Network Portfolio. This protocol included the other sites, but each site obtained their local ethical approval. The study complies with the principles outlined in the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent is obtained from all participants prior to any study-related procedures. Data confidentiality and participant privacy are maintained throughout the study in accordance with the General Data Protection Regulation.

### Coordination and validation

To ensure consistency and data quality across sites, standardised training sessions and inter-rater reliability assessments were conducted to validate clinical scales and ensure consistency in data collection. This process included video-based training, cross-site workshops and interrater reliability exercises facilitated by experts in psychopathology assessment before the recruitment started on each site. The same clinical research forms were used in all sites and each site had language-specific scales and tasks.

### Study procedure

Participants undergo a comprehensive assessment protocol, including clinical interviews, cognitive tasks and self-report questionnaires. The assessment is conducted over one or two sessions, depending on participant preference and tolerance, each lasting approximately 2–3 h.

- (a) Screening and Informed Consent: participants are screened for eligibility based on inclusion and exclusion criteria. Informed consent is obtained prior to any assessments.
- (b) Clinical Assessments: administration of standardised clinical rating scales by trained researchers.
- (c) Cognitive Tasks: participants complete a battery of computerised tasks designed to assess various components of motivation.
- (d) Self-Report Measures: participants complete questionnaires to evaluate subjective experiences related to motivation and negative symptoms.

### Clinical assessments

- (a) Positive and Negative Syndrome Scale: a clinician-rated scale with 30 items assessing positive symptoms, negative symptoms and general psychopathology. It uses a 7-point Likert scale to evaluate symptom severity.<sup>20</sup>
- (b) Brief Negative Symptom Scale: a 13-item clinician-rated scale designed to assess five negative symptom domains: blunted affect, alogia, anhedonia, asociality and avolition. Each item is rated on a 7-point scale.<sup>21</sup>
- (c) Calgary Depression Scale for Schizophrenia: a 9-item clinician-administered scale focusing on depressive symptoms specific to schizophrenia, differentiating them from negative or extrapyramidal symptoms.<sup>22</sup> In addition to the total score, we will also specifically examine the score of item 3: Self Depreciation, reflecting self-reported defeatist beliefs.
- (d) Personal and Social Performance Scale: a clinician-rated tool assessing social functioning across four domains: socially useful activities, personal and social relationships, self-care and disturbing and aggressive behaviours.<sup>23</sup>
- (e) Brief Assessment of Cognition in Schizophrenia (BACS): a 20-min validated cognitive battery to measure functions such as working memory, attention and verbal fluency.<sup>12</sup>

### Self-report measures

- (a) Apathy Motivation Index: an 18-item self-report questionnaire evaluating motivation across different life areas.<sup>24</sup>
- (b) Autism Spectrum Quotient: a self-report measure to screen for autistic traits that may overlap with negative symptoms.<sup>25</sup>
- (c) Apathy Evaluation Scale: a self-rated scale with 18 items designed to measure apathy, covering behavioural, cognitive and emotional domains.<sup>26</sup>

### Cognitive and behavioural tasks

The study incorporates four computerised tasks designed to investigate the three cognitive mechanisms underlying motivated behaviour (see above). These tasks, although novel to this population, have been validated in healthy individuals. The tasks were designed to be less taxing in terms of possible fatigue and to be 5 to 15 min long to facilitate engagement. Participants are seated comfortably, interacting with a computer via keyboard, mouse or touchscreen, with clear instructions and breaks provided to minimise fatigue. All tasks were programmed in JavaScript and run on a dedicated server with Just Another Tool for Online Studies for backend.<sup>27</sup>

Option generation task

**Objective:** To assess cognitive flexibility, creativity and action fluency we will deploy a simple, established task that has shown a




Fig. 2 Illustration of the option-generation task.

strong correlation with self-reported apathy in healthy people,<sup>28</sup> Lack of ability to generate options for behaviour may be particularly relevant to negative symptoms in schizophrenia. Along with the BACS tool, this task will test the executive cognition aspects of the motivational syndrome in schizophrenia.

**Task description:** Participants use a stylus pen to draw paths between two red circles on a touchscreen tablet (Fig. 2). All sites used tablets of the same make and model (Samsung Galaxy Tab S6 Lite). One red circle appeared at the top and one at the bottom of the display. In the first control condition, participants were asked to draw as many paths as possible between the bottom and top red circle for 30 s. In the main experimental condition, participants were asked to draw as many *different* paths as possible between the red circles. Drawn paths appeared on the screen as they were drawn and remained visible throughout the task to reduce working memory demands. Participants were free to create curved or straight paths, and the paths could overlap or intersect. To ensure paths were counted as valid, they had to start at the bottom circle and end at the top circle.

**Cognitive mechanism:** The control condition accounts for individual differences in movement speed. The main experimental condition measures fluency (the total number of paths generated) and uniqueness (the distinctiveness of each path relative to others). Uniqueness will be computed by quantifying the geometric (Euclidean) distance between paths, as done previously,<sup>28</sup> while accounting for basic differences in movement speed. This approach provides an objective measurement of creative output and flexibility, essential for understanding goal-directed behaviour.

**Task-specific hypothesis:** This task has not been previously applied in schizophrenia research. However, the task has been used in people with Parkinson's disease<sup>28</sup> and with depression. The hypothesis is that patients will show reduced fluency and reduced uniqueness, and reduced uniqueness would be related to executive dysfunction in patients, as measured using the BACS tool.

#### Milkman task

**Objective:** To operationalise the decision to switch in a time-constrained paradigm, as part of the motivational cognition mechanism. Specifically, the task examines reward-based decision-making in a foraging framework, evaluating tendencies to

persist with diminishing returns – a behaviour hypothesised to be altered in people with affective conditions and apathy<sup>29</sup> and to be dependent on dopamine.<sup>30</sup>

**Task description:** Participants are instructed to collect as much milk as possible over a 10-min period (Fig. 3). To milk a cow, they hold down the space bar, during which a bucket on the screen visually represents the accumulating milk. Participants are told that milking would become progressively harder over time. Milk accumulation follows an exponential decay function:

$$N(t) = N_0 e^{-\lambda t}$$

where  $N(t)$  is the instantaneous accumulation rate at time  $t$ ,  $N_0$  is the initial rate and  $\lambda$  is the rate of decline. There are four cow types, created by crossing two initial reward rates (0.01 or 0.02) with two decay rates ( $2e-4$  or  $4e-4$ ), resulting in a  $2 \times 2$  design: High-Slow, High-Fast, Low-Slow and Low-Fast. These conditions are designed to vary in overall profitability and optimal harvesting duration and are presented in a pseudorandom sequence such that every four-trial cycle includes one of each cow type.

When participants release the space bar, they enter a fixed 4-s travel period representing the time needed to reach the next cow. During this phase, a progress bar shows the remaining travel time, and the total milk earned so far is updated. Pressing the space bar prematurely during the travel screen triggers an on-screen warning lasting 2 s. A countdown timer displays the remaining time for the task, and participants' cumulative milk total is always visible. The task begins with a 1-min practice session to familiarise participants with the interface and response requirements.

**Cognitive mechanism:** The task assesses decision-making related to switching behaviours. The cognitive mechanism involves cost-benefit analysis and temporal discounting, designed and analysed using a foraging framework. The primary outcomes will be 'stay duration' and the related 'exit threshold' which is the reward rate at the decision to switch on each trial. Based on these, we will compute an 'offset' parameter, reflecting participant's overall tendency to stay longer or shorter than the optimal policy; and a 'scaling' parameter, reflecting how much participants exaggerate differences between conditions compared to the optimal policy.<sup>31</sup>

**Task-specific hypothesis:** This task has not been previously applied in schizophrenia research. We have recently validated the task in healthy participants in an online study.<sup>31</sup> Other foraging tasks have been used in the context of affective disorders,<sup>29</sup> attention-deficit hyperactivity disorder and Parkinson's disease.<sup>30</sup> In line with our




Fig. 3 Schematic of foraging in the milkman task.




Fig. 4 Schematic of the decision-making process in the tokens task.


previous findings in healthy controls,<sup>31</sup> we hypothesise that overstaying will be associated with general depressive symptoms, while deviation from optimal scaling would be associated with executive dysfunction, reflecting a failure to adapt appropriately to diminishing returns.

Tokens task

**Objective:** To examine decision-making under uncertainty and failure aversion, using a variant of a task from evidence accumulation literature,<sup>32</sup> as part of motivational cognition.

**Task description:** Participants completed a decision-making task in which they observe the movement of tokens from a central circle to two lateral circles and are asked to make a decision as to whether the left or right circle will have the most tokens by the end of the trial (Fig. 4). At the start of each trial, 15 tokens and a central cross are presented in a central circle. These tokens move incrementally, one at a time, towards either the left or right circle at pre-defined intervals. The movement pattern is determined by a pre-generated binary sequence, ensuring variability across trials while maintaining an equal number of left- and right-winning trials. The winning side

Stop the red hand on the red target  
Press SPACE to start/stop the hand



Time

Where did you stop the red hand?  
Press UP to move hand clockwise  
Press DOWN to move hand counterclockwise  
Press SPACE to confirm




Fig. 5 Schematic of the meta-cognition beliefs in the clock-stopping task.

was set to receive eight or nine tokens, ensuring that trials are not overly predictable.

Participants are instructed to make a decision as early as they felt, using the left or right arrow key to indicate their response. Once a decision is made, the cross moves to the chosen circle, and the remaining tokens are quickly distributed from the middle circle. If the choice is correct, the cursor turned green, a positive auditory cue is played and the text 'X number of tokens earned' appears in green, where X is the number of tokens earned on that trial. If incorrect, the cursor turns red, a negative auditory cue is played and the text 'no tokens earned' appears in red. If participants do not make a choice before all tokens had moved, a 'timeout' warning appears, and participants receive incorrect feedback (red circles and negative auditory cue).

Participants earn the number of tokens remaining in the middle circle when a correct decision is made. This speed accuracy trade-off is emphasised in the instructions given to participants, while they are encouraged to collect as many points as possible. Unlike previous studies,<sup>33</sup> we chose not to add an explicit penalty for incorrect choices and focused on the effect of implicit-loss feedback. Each participant completes 100 trials, with an equal number of left- and right-winning trials presented in a randomised order.

Choice behaviour will be modelled using a Bayesian decision framework in which participants update beliefs about the eventual majority pile on each token draw. At each state, the model evaluates the value of choosing left, right or waiting, with choice values determined by the posterior probability of each pile being the majority. Two free parameters were estimated: a subjective-punishment parameter capturing the subjective cost of making an incorrect choice and a cost-of-waiting parameter representing the individual's opportunity cost of time. Actions are generated probabilistically using a softmax rule over the three action values, and parameters will be fit by maximising the log-likelihood of the observed sequences of waits and choices.

**Cognitive mechanism:** The task evaluates the decision of when to act and which action to choose. The main model free outcome measures are number of tokens drawn until decision and response

('right' or 'left'). The computational model parameters will compute each participant's loss aversion and opportunity cost of time, with the hypothesis that people with schizophrenia will require more evidence before committing to a choice due to loss aversion, over and above general slowness.

**Task-specific hypothesis:** This task has not been previously applied in schizophrenia research. It is expected to reveal increased loss aversion and reduced opportunity cost of time in patients. While increased loss aversion is hypothesised to correlate with meta-cognition measures, sensitivity to the opportunity cost of time is expected to correlate with executive dysfunction.

Clock stopping task (performance beliefs task)

**Objective:** To explore meta-cognition deficits in schizophrenia, particularly defeatist performance beliefs, which suggest that patients generalise negative thoughts about their abilities, which leads them to avoid goal-directed behaviours.<sup>16</sup>

**Task description:** The Performance Beliefs Task (Fig. 5) involves participants estimating their ability to stop a moving clock hand at a target location ('time'). The task has two phases: First, during the action (hand-stopping) phase, participants observe a moving red clock hand that rotated clockwise or counterclockwise and are asked to stop it as close as possible to a predesignated target time (marked in colour red). They press the space bar to stop the red clock hand. Second, after stopping the clock hand, during the estimation phase, the clock hand disappears, and the target time turns black again. Participants are prompted to estimate where they stopped the red hand by manually adjusting a second blue clock hand using the arrow keys. The experiment consists of 50 trials, with pseudo-randomised hand movement directions and stopping targets. Participants are also given a time limit for making their estimates. If they respond too late, they receive a 'timeout' message and repeat the trial.

**Cognitive mechanism:** The task was designed to assess meta-cognition beliefs about performance, testing how well participants

could predict and evaluate their own actions. Each trial has two main outcome measures: performance error, calculated as the difference between the target position and where the red hand was stopped, and estimation error, calculated as the difference between their estimated and actual stopping position. These measures can be fit using a Bayesian model that assumes that belief about the stopping position combines noisy sensory input with prior expectations about success (target position).<sup>34</sup> To account for non-integration trials,<sup>35</sup> the model will be extended with a non-updating function that probabilistically converts moderate prescribed updates into either non-updates (reliance on the prior) or full updates (reliance on sensory evidence).<sup>35</sup> In this framework, small discrepancies between prior expectations and sensory evidence increase the probability of relying on the prior, large discrepancies increase the probability of relying on sensory evidence and intermediate discrepancies favour Bayesian integration of both sources of information. The parameters will measure prior precision (expectation of success), sensory noise and non-updating thresholds. We hypothesise that prior precision will be associated with self-depreciation.

**Task-specific hypothesis:** This task has not been previously applied in schizophrenia research. Similar paradigms have been used in Parkinson's disease and healthy populations,<sup>36,37</sup> We hypothesise that patients will exhibit diminished expectation of success, compared with the typical optimistic expectations people show in the task.<sup>34</sup>

### Cross-task analysis plan

Data from the four experimental tasks will be pooled for cross-task analyses. Specifically, as per one of the main aims of CHANSS, we sought to capture clusters or subtypes of motivational deficits across patients. As set out at the beginning of this paper, we expect these clusters to overlap and to have a hierarchical structure, with executive cognition influencing both motivational and meta-cognition, and with motivational cognition influencing meta-cognition. To capture this, we will use Gaussian Mixture Modelling (GMM), which is ideally suited for this nested structure, as it models clusters as overlapping Gaussian distributions and provides posterior probabilities of cluster membership rather than 'hard' cluster assignments.<sup>38</sup> First, as GMMs use full covariance matrices which capture the interdependencies inherent in our hierarchical model, where deficits in lower-order functions (executive) systematically affect higher-order functions (motivational, meta-cognition). This covariance structure allows GMM to model the cascading effects that define our theoretical hierarchy. Second, the 'soft' clustering approach of GMMs aligns with our aim to compute the relative contribution of each cognitive mechanism to apathy.

As we expect patients to vary significantly in processing speed, which could confound some of the results, we will account for individual differences. To this end, we will compute a composite processing speed measure across tasks, derived from the first principal component of the following indices: (a) overall score in the tokens motor task from BACS; (b) mean cross-trial maximum speed of path drawing in the control condition of the option-generation task; (c) median latency in the milkman task; and (d) median reaction time in the estimation phase of the clock-stopping task.

Another possible confounder we will consider is the testing site. To address this, we will test for differences in clustering results between sites. Specifically, we will test whether the different site countries (the UK, Spain and China which would recruit a roughly similar number of participants each) will have different clustering probabilities in the GMMs.

### Power calculation

As our principal aim was to investigate the cognitive mechanisms of negative symptoms, our study was powered for the within-patient group analyses. These included (a) task-specific correlations of the task parameters and clinical or cognitive scale; and (b) cross-task subgroup identification. As a secondary aim and for the comparison with normative data in the tasks, we sought to collect a similar sample size of age- and gender-matched healthy controls.

For the task-specific correlations, considering we had six *a priori* correlations of interest across all tasks (uniqueness parameter in option-generation task; offset and scaling parameters in the milkman task; loss aversion and opportunity cost of time in the tokens task; and prior precision in the clock-stopping task), a sample size of 162 individuals would provide 90% power to detect correlations with medium effect size ( $r=0.3$ ) at the level of  $\alpha=0.05/6=0.008$ . Moreover, based on previous literature<sup>38</sup> and simulation for Gaussian Mixture Models with six features and three hierarchical clusters with a good ( $d=1$ ) separation, this sample size would provide moderate power (70–80% from simulations) to detect the three hypothesised clusters (equal number of participants per cluster assumed).

### Data management

All data are collected using secure, encrypted electronic data capture systems. Data is pseudo-anonymised on each site, assigning a unique identifier (e.g. CC001) to each volunteer. Data are stored in compliance with local regulations and specifically local data protection regulations. Quality control measures include regular audits and inter-rater reliability assessments for clinical ratings.

## Discussion

Along with cognitive deficits, negative symptoms are the most pervasive in schizophrenia, determining long-term prognosis and jeopardising functional recovery.<sup>39</sup> However, the advances in treating psychotic symptoms have not been mirrored in improving motivation in schizophrenia. There are different culprits for this lack of advance, including the limitation of the current scales and the amalgamation of apathy with emotional expression into the unitary concept of negative symptoms. We have previously highlighted the difficulties in the current scales as well as the need for focusing on either motivation or emotional deficits when studying their biology and when testing new treatments.<sup>40</sup>

This large, multicentre, multicultural study aims to identify the cognitive and clinical factors underlying the motivational syndrome in schizophrenia. It integrates three leading hypotheses of apathy: that it arises from executive dysfunction, impaired motivational decision-making or meta-cognition deficits such as defeatist beliefs. The study investigates whether distinct profiles of these deficits exist and how they interact. While we acknowledge that executive, motivational and meta-cognition mechanisms are interrelated, we argue that quantifying their relative contributions in individual patients is essential – particularly given the high heterogeneity of schizophrenia. Such profiling could inform personalised treatment strategies, moving beyond the broadly applied pharmacological interventions that have shown limited success to date.<sup>41</sup> For example, individuals with prominent defeatist beliefs may respond better to cognitive behavioural therapy, whereas those with executive impairments may benefit more from cognitive remediation. Furthermore, by accounting for secondary factors that influence motivational deficits – such as depression or medication

side-effects – we may identify more immediate, practical interventions, such as antidepressant use or antipsychotic dose adjustments. These insights can help tailor clinical management to the needs of individual patients and lay the groundwork for stratified treatment approaches.

In sum, the CHANSS study offers a chance to disentangle the complex syndrome of poor motivation, in order to enable implementable interventions and informing future mechanism-led clinical trials.

**Noah Wolpe**, MD, PhD, Department of Physical Therapy, The Stanley Steyer School of Health Professions, Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; and Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel; **Claudia Aymerich** , MD, PhD, Spanish Network for Research in Mental Health, Carlos III Institute (CIBERSAM ISCIII), Madrid, Spain; Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; and Child and Adolescent Mental Health Services, South London and Maudsley NHS Foundation Trust, London, UK; **Ying Jin**, MD, Clinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, China; **Marta Martín-Subero**, MD, PhD, Spanish Network for Research in Mental Health, Carlos III Institute (CIBERSAM ISCIII), Madrid, Spain; and Institute of Mental Health, Parc de Salut Mar, Barcelona, Spain; **Paloma Fuentes-Perez**, MSc, Spanish Network for Research in Mental Health, Carlos III Institute (CIBERSAM ISCIII), Madrid, Spain; Hospital del Mar Foundation Medical Research Institute (IMIM), Barcelona, Spain; and Health Research Institute Valdecilla (IDIVAL), Santander, Spain; **Claudia Ovejas-Catalan**, MSc, Spanish Network for Research in Mental Health, Carlos III Institute (CIBERSAM ISCIII), Madrid, Spain; Hospital del Mar Foundation Medical Research Institute (IMIM), Barcelona, Spain; and Health Research Institute Valdecilla (IDIVAL), Santander, Spain; **Sara Salas-Rad**, MSc, Spanish Network for Research in Mental Health, Carlos III Institute (CIBERSAM ISCIII), Madrid, Spain; Hospital del Mar Foundation Medical Research Institute (IMIM), Barcelona, Spain; and Health Research Institute Valdecilla (IDIVAL), Santander, Spain; **Renata Zirilli**, MSc, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK; **Sophie Shatford**, MSc, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK; **Rebecca Cox**, MSc, Clinical Research Unit, South West London & St George's Mental Health NHS Trust, London, UK; **Megan Cartier**, MSc, Clinical Research Unit, South West London & St George's Mental Health NHS Trust, London, UK; **Ana Catalan**, MD, PhD, Spanish Network for Research in Mental Health, Carlos III Institute (CIBERSAM ISCIII), Madrid, Spain; Department of Neuroscience, University of the Basque Country UPV/EHU, Biscay, Spain; Department of Psychiatry, Basurto University Hospital, OSI Bilbao-Basurto, Bilbao, Spain; Early Psychosis: Interventions and Clinical-detection (EPIC) Lab, Department of Psychosis Studies, King's College London, London, UK; and Biobizkaia Health Research Institute, Barakaldo, Bizkaia, Spain; **Anna Mane**, MD, PhD, Spanish Network for Research in Mental Health, Carlos III Institute (CIBERSAM ISCIII), Madrid, Spain; and Grup MERITT, Sant Joan de Deu Research Institute, Parc Sanitari Sant Joan de Déu, Spain; **John Pratt**, MSc, Research Team, Humber NHS Foundation Trust, Hull, UK; **Lisa Airey**, MSc, Research Team, Humber NHS Foundation Trust, Hull, UK; **Paul Stanley**, RN, Grounded Research, Rotherham, Doncaster and South Humber NHS Foundation Trust, Doncaster, UK; **Adrienne Close**, MSc, Grounded Research, Rotherham, Doncaster and South Humber NHS Foundation Trust, Doncaster, UK; **Andrew Hall**, MSc, Grounded Research, Rotherham, Doncaster and South Humber NHS Foundation Trust, Doncaster, UK; **Javier Vazquez-Bourgon**, MD, PhD, Spanish Network for Research in Mental Health, Carlos III Institute (CIBERSAM ISCIII), Madrid, Spain; Hospital del Mar Foundation Medical Research Institute (IMIM), Barcelona, Spain; Health Research Institute Valdecilla (IDIVAL), Santander, Spain; and University Hospital Marqués de Valdecilla - University of Cantabria, Santander, Spain; **Francesco del Santo**, MD, PhD, Spanish Network for Research in Mental Health, Carlos III Institute (CIBERSAM ISCIII), Madrid, Spain; and University of Oviedo, Health Research Institute Principado de Asturias (ISPA) and Health Service of the Principality of Asturias (SESPA), Oviedo, Spain; **Maria-Paz Garcia-Portilla**, MD, PhD, Spanish Network for Research in Mental Health, Carlos III Institute (CIBERSAM ISCIII), Madrid, Spain; and University of Oviedo, Health Research Institute Principado de Asturias (ISPA) and Health Service of the Principality of Asturias (SESPA), Oviedo, Spain; **Nuria Segarra**, PhD, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK; **Yi-Jie Zhao**, PhD, Clinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, China; **Paul C. Fletcher**, PhD, MBBS, FRCPsych, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK; and Department of Psychiatry, University of Cambridge, Cambridge, UK; **Masud Husain**, DPhil, FRCP, Department of Experimental Psychology, University of Oxford, Oxford, UK; and Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; **Peter B. Jones** , PhD, FRCPsych, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK; and Department of Psychiatry, University of Cambridge, Cambridge, UK; **Emilio Fernandez-Egea** , MD, PhD, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK; and Department of Psychiatry, University of Cambridge, Cambridge, UK

**Correspondence:** Emilio Fernandez-Egea. Email: [Ef280@cam.ac.uk](mailto:Ef280@cam.ac.uk)

First received 10 May 2025, final revision 26 Aug 2025, accepted 16 Sep 2025

## Data availability

Anonymised data supporting the findings of this project will be made publicly available in the Open Science Framework (OSF) repository following publication of the initial task-specific and cross-task studies based on this dataset. At that point, the dataset will be deposited and assigned a persistent DOI, and the link will be provided in the final published article.

## Author contributions

N.W., P.C.F., M.H., P.B.J. and E.F.-E. conceived and designed the study. Data were collected by N.W., C.A., Y.J., M.M.-S., P.F.-P., C.O.-C., S.S.-R., R.Z., S.S., R.C., M.C., A. Catalan, A.M., J.P., L.A., P.S., A. Close, A.H., J.V.-B., F.d.S., M.-P.G.-P., N.S., Y.-J. and E.F.-E. Analyses were performed by N.W. and E.F.-E. Interpretation of results was undertaken by N.W., Y.Z., A.C., A.M., M.H. and E.F.-E. The manuscript was drafted by N.W. and E.F.-E. Critical revision and editing were carried out by N.W., P.B.J., M.H. and E.F.-E. N.W. and E.F.-E. provided supervision and act as guarantors of the work.

## Funding

N.W. was funded by an Israel Science Foundation Personal Research Grant (1603/22), NSF-BF-NIH Computational Neuroscience (CRCNS) grant (2024628) and previously by a National Institute for Health and Care Research (NIHR) Academic Clinical Fellowship (ACF-2019-14-013). J.V.-B. is supported by ISCIII (PI20/01279) and Plan Nacional sobre Drogas (2021/079; EXP2022/08898). N.S. is supported by the NIHR Greenhoots programme. P.C.F. is funded by the Bernard Wolfe Health Neuroscience Fund and a Wellcome Trust Investigator Award (Reference No. 206368/Z/17/Z). M.H. is supported by the Wellcome Trust and the NIHR Oxford Health Biomedical Research Centre. P.B.J. is supported by NIHR (PGAR 0616-20003) and Wellcome, and is co-founder of Cambridge Adaptive Testing Ltd. E.F.-E. is supported by the 2022 MRC/NIHR CARP award (MR/W029987/1), specifically to this project. All research at the Department of Psychiatry in the University of Cambridge is supported by the NIHR Cambridge Biomedical Research Centre (NIHR203312) and the NIHR Applied Research Collaboration East of England. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

## Declaration of interest

C.A. is supported by the Alicia Koplowitz Foundation and has received personal fees or grants from Janssen Cilag and Neuraxpharm, outside the current work. C.O.-C. reports having received support to attend scientific meetings from Janssen, ROVI and Lundbeck in the last five years. She is also supported by the Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness. A.M. has received support to attend meetings or served as an advisor or speaker for Janssen Cilag, Neuraxpharm, Otsuka, Lundbeck and Angellini. J.V.-B. has received financial support to attend scientific meetings or as advisor or speaker at educational events from Janssen, Lundbeck and Angellini Pharma. M.H. is a consultant for NeuHealth. E.F.-E. has received consultancy honoraria from Boehringer-Ingelheim (2022), Atheneum (2022) and Rovi (2022–24), speaker fees by Adamed (2022–24), Otsuka (2023) and Viatrix (2024) and training and research material from Merz (2020) and editorial honoraria from the Spanish Society of Psychiatry and Mental Health (2023). E.F.-E. is also deputy editor of the *British Journal of Psychiatry*, but has no role in the evaluation of this paper. The remaining authors report no conflicts of interest with this project.

## Transparency declaration

N.W. and E.F.-E. affirm that the manuscript is an honest, accurate and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

## References

- Prince M, Patel V, Saxena S, Maj M, Maselko J, Phillips MR, et al. No health without mental health. *Lancet* 2007; **370**: 859–77.
- Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes: II. Positive and negative symptoms and long-term course. *Arch General Psychiatry* 1991; **48**: 978.
- Ahmed AO, Kirkpatrick B, Galderisi S, Mucci A, Rossi A, Bertolino A, et al. Cross-cultural validation of the 5-factor structure of negative symptoms in schizophrenia. *Schizophr Bull* 2019; **45**: 305–14.
- Wolpe N, Fernandez-Egea E. The structural stability of negative symptoms over time. *BJPsyOpen* 2023; **9**: e208.
- Kaliuzhna M, Kirschner M, Carruzzo F, Hartmann-Riemer MN, Bischof M, Seifritz E, et al. How far to go in deconstructing negative symptoms? Behavioural and neural level evidence for the amotivation domain. *Schizophr Res* 2021; **236**: 41–7.
- Wolpe N, Chen S, Kirkpatrick B, Jones PB, Jenkins C, Cardinal RN, et al. Longitudinal effect of clozapine-associated sedation on motivation in schizophrenia: naturalistic longitudinal study. *Br J Psychiatry* 2023; **223**: 295–7.
- Wolpe N, Vituri A, Jones PB, Shahar M, Fernandez-Egea E. The longitudinal structure of negative symptoms in treatment resistant schizophrenia. *Compreh Psychiatry* 2024; **128**: 152440.
- Husain M, Roiser JP. Neuroscience of apathy and anhedonia: a transdiagnostic approach. *Nat Rev Neurosci* 2018; **19**: 470–84.
- Barch DM, Treadway MT, Schoen N. Effort, anhedonia, and function in schizophrenia: reduced effort allocation predicts amotivation and functional impairment. *J Abnorm Psychol* 2014; **123**: 387–97.
- Bègue I, Kaiser S, Kirschner M. Pathophysiology of negative symptom dimensions of schizophrenia – current developments and implications for treatment. *Neurosci Biobehav Rev* 2020; **116**: 74–88.

- 11 Dibben CRM, Rice C, Laws K, McKenna PJ. Is executive impairment associated with schizophrenic syndromes? A meta-analysis. *Psychol Med* 2009; **39**: 381–92.
- 12 Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. *Schizophr Res* 2004; **68**: 283–97.
- 13 Culbreth AJ, Moran EK, Barch DM. Effort-based decision-making in schizophrenia. *Curr Opin Behav Sci* 2018; **22**: 1–6.
- 14 Blouzard E, Pouchon A, Polosan M, Bastin J, Dondé C. Effort-cost decision-making among individuals with schizophrenia: a systematic review and meta-analysis. *JAMA Psychiatry* 2023; **80**: 548–57.
- 15 Saleh Y, Jarratt-Barnham I, Petitet P, Fernandez-Egea E, Manohar SG, Husain M. Negative symptoms and cognitive impairment are associated with distinct motivational deficits in treatment resistant schizophrenia. *Mol Psychiatry* 2023; **28**: 4831–41.
- 16 Grant PM, Beck AT. Defeatist beliefs as a mediator of cognitive impairment, negative symptoms, and functioning in schizophrenia. *Schizophr Bull* 2009; **35**: 798–806.
- 17 Culbreth AJ, Chib VS, Riaz SS, Manohar SG, Husain M, Waltz JA, et al. Increased sensitivity to effort and perception of effort in people with schizophrenia. *Schizophr Bull* 2025; **51**: 696–709.
- 18 Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. *Lancet Psychiatry* 2018; **5**: 664–77.
- 19 World Health Organization. *The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines*. WHO, 1992.
- 20 Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. *Schizophr Bull* 1987; **13**: 261–76.
- 21 Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, et al. The brief negative symptom scale: psychometric properties. *Schizophr Bull* 2011; **37**: 300–5.
- 22 Addington D, Addington J, Maticka-tyndale E. Assessing depression in schizophrenia: the Calgary depression scale. *Br J Psychiatry* 1993; **163**: 39–44.
- 23 Morosini PI, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. *Acta Psychiatr Scand* 2000; **101**: 323–9.
- 24 Ang YS, Lockwood P, Apps MAJ, Muhammed K, Husain M. Distinct subtypes of apathy revealed by the Apathy Motivation Index. *PLOS One* 2017; **12**: e0169938.
- 25 Baron-Cohen S, Wheelwright S, Skinner R, Martin J, Clubley E. The autism-spectrum quotient (AQ): evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians. *J Autism Dev Disord* 2001; **31**: 5–17.
- 26 Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the apathy evaluation scale. *Psychiatry Res* 1991; **38**: 143–62.
- 27 Lange K, Kühn S, Filevich E. 'Just Another Tool for Online Studies' (JATOS): an easy solution for setup and management of web servers supporting online studies. *PLOS One* 2015; **10**: e0130834.
- 28 Ang YS, Manohar S, Plant O, Kienast A, Le Heron C, Muhammed K, et al. Dopamine modulates option generation for behavior. *Curr Biol* 2018; **28**: 1561–9.
- 29 Bustamante LA, Barch DM, Solis J, Oshinowo T, Grahek I, Konova AB, et al. Major depression symptom severity associations with willingness to exert effort and patch foraging strategy. *Psychol Med* 2024; **54**: 4396–407.
- 30 Le Heron C, Kolling N, Plant O, Kienast A, Janska R, Ang YS, et al. Dopamine modulates dynamic decision-making during foraging. *J Neurosci* 2020; **40**: 5273–82.
- 31 Wolpe N, Scott D, Salomon ML, Nassar MR, Fletcher P, Fernandez-Egea E. Suboptimality in foraging and its association with age and mental health factors. *PsyArXiv* [Preprint] 2025. Available from: [https://osf.io/bc7hp\\_v2](https://osf.io/bc7hp_v2) [cited 3 Apr 2025].
- 32 Thura D, Cisek P. The basal ganglia do not select reach targets but control the urgency of commitment. *Neuron* 2017; **95**: 1160–70.
- 33 Derosiere G, Thura D, Cisek P, Duque J. Motor cortex disruption delays motor processes but not deliberation about action choices. *J Neurophysiol* 2019; **122**: 1566–77.
- 34 Wolpe N, Wolpert DM, Rowe JB. Seeing what you want to see: priors for one's own actions represent exaggerated expectations of success. *Front Behav Neurosci* 2014; **8**: 232.
- 35 Nassar MR, Waltz JA, Albrecht MA, Gold JM, Frank MJ. All or nothing belief updating in patients with schizophrenia reduces precision and flexibility of beliefs. *Brain* 2021; **144**: 1013–29.
- 36 Wolpe N, Nombela C, Rowe JB. Dopaminergic modulation of positive expectations for goal-directed action: evidence from Parkinson's disease. *Front Psychol* 2015; **6**: 1514.
- 37 Hezemans FH, Wolpe N, Rowe JB. Apathy is associated with reduced precision of prior beliefs about action outcomes. *J Exp Psychol Gen* 2020; **149**: 1767–77.
- 38 McLachlan G, Peel D. *Finite Mixture Models*. 1st ed. Wiley, 2000.
- 39 Konstantakopoulos G, Ploumpidis D, Oulis P, Patrikelis P, Soumani A, Papadimitriou GN, et al. Apathy, cognitive deficits and functional impairment in schizophrenia. *Schizophr Res* 2011; **133**: 193–8.
- 40 Wolpe N, Perrottelli A, Giuliani L, Yang Z, Rekhi G, Jones PB, et al. Measuring the clinical dimensions of negative symptoms through the Positive and Negative Syndrome Scale. *Eur Neuropsychopharmacol* 2025; **93**: 68–76.
- 41 Galderisi S, Kaiser S, Bitter I, Nordentoft M, Mucci A, Sabé M, et al. EPA guidance on treatment of negative symptoms in schizophrenia. *Eur Psychiatry* 2021; **64**: e21.